AbbVie Inc.
ABBV
$150.0
| Price | Change | Change % | Marketcap | Open | High | Low | Close | Volume | 52 Week Range | EPS | Dividend Rate | Dividend Yield | Sector | Industry | Employees | Country | Last Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $150.0 | $0.57 | 0.38% | 267.5B | $149.5 | $150.1 | $147.8 | $150.6 | 8,404,961 | 6.971 | 5.42 | 3.5996545 | Healthcare | Drug Manufacturers—General | 50,000 | United States | 1 day ago |
AbbVie Historical Market Cap (2012 – 2022)
| Year | Market cap |
|---|---|
| 2022 | $267,513,004,032.0 |
| 2021 | $239.37 B |
| 2020 | $189.17 B |
| 2019 | $130.94 B |
| 2018 | $136.33 B |
| 2017 | $154.39 B |
| 2016 | $101.76 B |
| 2015 | $95.37 B |
| 2014 | $104.14 B |
| 2013 | $83.82 B |
| 2012 | $53.97 B |
AbbVie Annual Revenue & Earnings (2011 – 2022)
| Year | Revenue | Earnings |
|---|---|---|
| 2021 | $55.16 B | $9.68 B |
| 2020 | $45.80 B | $5.85 B |
| 2019 | $33.26 B | $10.21 B |
| 2018 | $32.75 B | $6.54 B |
| 2017 | $28.21 B | $8.87 B |
| 2016 | $25.63 B | $8.93 B |
| 2015 | $22.85 B | $7.36 B |
| 2014 | $19.96 B | $2.79 B |
| 2013 | $18.79 B | $5.63 B |
| 2012 | $18.37 B | $5.71 B |
| 2011 | $17.44 B | $4.29 B |
About The AbbVie Inc. Company
AbbVie Inc.Sector: Healthcare
Industry: Drug Manufacturers—General
Exchange: NYQ
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
0 Comments